What Dafalgan Codeine Treats: Main Uses and Benefits

The combined analgesic is commonly used in clinical settings to provide supportive symptomatic relief when additional symptom management is appropriate. The primary therapeutic purpose is the management of pain. This dual-agent product is applied across domains where additional symptomatic support is needed, primarily focusing on pain of mild to moderate severity.

It is commonly used to help with pain originating from various sources, including headaches and migraines, dental discomfort, muscle pain, back discomfort, and dysmenorrhea (menstrual pain). This combination is applicable in conditions marked by acute or recurrent episodes of pain and is often used when additional management of discomfort is required.

“It is relevant in settings where symptoms become temporarily overwhelming, and contributes to easing the overall symptom load.”

This combination also plays a role in managing both pain and elevated body temperature concurrently, and is relevant in contexts involving heightened systemic burden, such as during common fever-inducing illnesses. It may help patients cope more steadily with symptom fluctuations and contributes to easing the overall symptom load.

Quick Fact: Relief for Pain Requiring Additional Support The combination is positioned as a second-step analgesic for pain that requires additional symptomatic assistance. It supports functional stability during short-term, acute phases of moderate discomfort.

Regulatory References

1. NIH MedlinePlus Drug Information overview

This section outlines the official eligibility and non-eligibility requirements for Dafalgan Codeine, strictly based on authoritative government regulatory documents from agencies such as the FDA, EMA, and TGA.

Contraindicated Populations (Must Not Use)

Use of this medicine is prohibited for specific groups due to unacceptable risks, as defined in official regulatory labeling:

• Age: Children younger than 12 years of age for any indication.
• Surgical History: Pediatric patients (under 18 years) following tonsillectomy and/or adenoidectomy for obstructive sleep apnoea syndrome.
• Physiology: Women who are breastfeeding.
• Metabolism: Patients of any age known to be CYP2D6 ultra-rapid metabolizers.
• Conditions: Patients with significant respiratory depression, acute or severe bronchial asthma (in an unmonitored setting), gastrointestinal obstruction (e.g., paralytic ileus), or concurrent use of Monoamine Oxidase Inhibitors (MAOIs) or use within 14 days.

Populations Requiring Restricted or Conditional Use

Use is subject to caution, monitoring, or dose adjustment in populations with specific health conditions:

• Organ Function: Patients with hepatic (liver) impairment or renal (kidney) impairment.
• Age: Elderly patients are more susceptible to adverse effects.
• Adolescents: Patients 12 to 18 years of age with pre-existing risk factors for breathing problems (e.g., obesity, severe lung disease) require special consideration.

Interactions with other medicines and products

This section outlines interactions based on official regulatory labeling. Co-administration of Dafalgan Codeine with certain medicines or substances can alter the levels of the active ingredients, paracetamol and codeine, or produce combined effects on the body.

Clinically Significant Interaction Categories

Practical Constraints and Requirements

• CNS Depressants: Concomitant use with CNS depressants may result in profound sedation and life-threatening respiratory depression; close monitoring is required.
• Codeine Metabolism: Agents that inhibit the CYP2D6 enzyme may lead to reduced analgesic efficacy of codeine due to decreased formation of the active metabolite, morphine.
• Paracetamol Effects: Long-term co-administration with oral anticoagulants (e.g., warfarin) requires careful monitoring of the INR. Paracetamol absorption is accelerated by drugs like metoclopramide and reduced by cholestyramine.

Dafalgan Codeine is a combination product where both components exert distinct pharmacodynamic mechanisms. Codeine functions as a prodrug; it is O-demethylated in the liver primarily by the Cytochrome P450 2D6 (CYP2D6) enzyme to its active metabolite, morphine. Morphine acts as a full agonist at the mu-opioid receptor (mu-OR), which are G-protein coupled receptors predominantly localized in the central nervous system (CNS). Activation of mu-OR couples to the inhibitory Gi protein signaling pathway, leading to a decrease in intracellular cyclic AMP (cAMP) synthesis. This downstream cascade results in hyperpolarization of the neuronal cell membrane via increased potassium efflux and inhibition of voltage-gated calcium channel opening, reducing neuronal excitability and neurotransmitter release in the afferent nociceptive pathways. The resulting system-level modulation is a generalized suppression of ascending nociceptive signal transmission. Paracetamol, the second component, is thought to act centrally by inhibiting a variant of the cyclooxygenase (COX) enzyme, likely COX-3 or central isoforms of COX-1/2, thereby reducing the synthesis of prostaglandins within the CNS. The consequence is a modification of local inflammatory mediator activity within the central nervous system.

How to Use Dafalgan Codeine: Administration Guidelines

Dafalgan Codeine is an oral combination product containing Acetaminophen (Paracetamol) and Codeine. The medicine is available in forms such as tablets (e.g., 500 mg/30 mg strength) and oral solutions.

Dosing and Administration Rules

The following table summarizes key administration parameters for adults (ge 50 kg).

Population-Specific Adjustments

Specific adjustments are necessary for vulnerable groups:

• Renal Impairment: The minimum interval between doses must be extended. For severe impairment (creatinine clearance < 10 mL/min), the interval is increased to 8 hours.
• Hepatic Impairment / Low Body Weight (< 50 kg): The maximum daily dose of the Paracetamol component is reduced, typically not exceeding 3 g (or 60 mg/kg/day).
• Older Adults: A reduced or lower initial dose may be necessary, and dosage should be adjusted based on individual response and tolerance.

Proper use is structured by the strict limits on frequency and duration, alongside the mandatory procedural rule to never take any other Paracetamol-containing product concurrently to prevent accidental overdose of the non-opioid component.

Research evidence / Overview of Studies for Dafalgan Codeine

This section provides a factual overview of the types of research and clinical situations that have been explored for the combination of acetaminophen and codeine, focusing on study design, measured outcomes, and documented research limitations. This information is intended for general context and is not a substitute for professional medical guidance.

Evidence for Use in Acute Pain Management

This evidence base primarily relates to conditions associated with acute or disruptive episodes of physical discomfort, such as pain following surgical procedures or a trauma. The research has mainly focused on understanding how symptoms change over time and how outcomes related to physical discomfort evolve over defined, short time intervals.

Study Design and Outcomes Examined

Research in this area includes systematic reviews and meta-analyses that aggregate data from numerous Randomized Controlled Trials (RCTs). Researchers monitored outcomes related to physical discomfort, specifically measuring the proportion of participants who achieved a certain pre-defined level of pain relief and the time until patients sought rescue medication. Findings describe patterns observed in the studies where the combination was evaluated in controlled trial settings, and research has explored outcomes related to the duration of observed analgesic action.

Evidence for Use in Chronic Pain Conditions

Research has also examined the combination’s use in conditions marked by functional limitations, such as osteoarthritis of the hip or knee and chronic low back discomfort. The studies explored outcomes related to daily functioning or activity level and patient-reported outcomes describing perceived discomfort over several weeks. Findings indicate that some research observed measured changes in pain and function scores in certain patient groups with osteoarthritis, but the overall evidence quality varies across studies.

Long-Term Studies and Follow-Up

The follow-up durations were limited for the highest-quality evidence in acute settings. However, some individual trials examining chronic pain studies monitored patient responses up to 12 weeks, though long-term outcome data are not fully established. Research has also explored outcomes in older adults, but evidence is limited in the pediatric population, and studies focus on certain subgroups.

What is Still Uncertain About the Combination

One major element of uncertainty is the documented variability in individual response to the codeine component. Studies describe that the analgesic effect of the codeine portion may depend on an individual's unique metabolism, meaning some people may experience a less pronounced effect. Research also highlights that studies primarily focus on single-dose efficacy, and comparative evidence is lacking against other analgesic treatments in various settings. Furthermore, subgroup findings are uncertain in many areas outside of acute postoperative care.

Key Studies & References Codeine for Pain Related to Osteoarthritis of the Knee and Hip: A Review of Clinical Effectiveness (NCBI/CADTH)

Common questions about Dafalgan Codeine (FAQ)

Q: What is Dafalgan Codeine, and what is it used for?

A: Dafalgan Codeine is a combination medicine containing paracetamol (an analgesic and antipyretic) and codeine (an opioid analgesic). It is used for the short-term relief of moderate pain that is not adequately relieved by other pain relievers, such as paracetamol or ibuprofen, when used alone.

Q: How does Dafalgan Codeine work?

A: The two active ingredients work differently to relieve pain.

• Paracetamol works in the central nervous system to relieve pain and reduce fever.
• Codeine belongs to a group of medicines called opioid analgesics. It works in the brain and spinal cord by acting on specific receptors to block pain signals and change how you perceive pain. Codeine is converted into morphine by an enzyme in the liver, and this morphine is the substance that produces the pain-relieving effect.

Q: What are the possible side effects of Dafalgan Codeine?

A: Common side effects of Dafalgan Codeine are similar to those of other opioids and may include:

• Constipation
• Drowsiness or dizziness
• Nausea and vomiting
• Headache
• Fatigue

Serious side effects include slow or shallow breathing, confusion, sleepiness, or small pupils. You should seek immediate medical attention if you notice signs of serious side effects.

Q: Can I become addicted to Dafalgan Codeine?

A: As an opioid-containing medicine, there is a risk of developing physical dependence or addiction (also known as hazardous and harmful use) even when taking it exactly as prescribed. Physical dependence means your body may experience withdrawal symptoms if you stop taking the medicine suddenly. These symptoms can include restlessness, irritability, and anxiety. Your doctor will monitor your use to help minimize this risk, and you should always take it as prescribed.

Q: Can I take other medicines containing paracetamol or codeine while using Dafalgan Codeine?

A: No, you must not take any other medicines that contain paracetamol or codeine while you are taking Dafalgan Codeine. Taking other products containing these ingredients could lead to an accidental overdose, which may be harmful or even fatal.

Q: Is it safe to drive or operate machinery while taking this medicine?

A: No, Dafalgan Codeine can cause dizziness, drowsiness, or affect your vision. If you are affected in this way, you must not drive or operate heavy machinery. You should be cautious, especially when first starting the medicine or after a dose increase.

Q: Can I drink alcohol while taking Dafalgan Codeine?

A: No, you must not drink alcohol while taking this medicine. The combination of alcohol and Dafalgan Codeine can increase the risk of serious side effects, such as profound sedation, severe drowsiness, respiratory depression, coma, and death.

How to Store and Dispose of Dafalgan Codeine?

Storage Conditions

Official regulatory labeling dictates that Dafalgan Codeine must be stored at a temperature below 25°C (77°F) and kept in a cool, dry place. The medication must remain in its original container to protect it from light and should not be used past the expiration date on the package.

Due to the presence of codeine, the product must be stored in a safe, secured location and kept strictly out of the sight and reach of children.

Disposal Instructions

Unused or expired Dafalgan Codeine should be disposed of using an authorized drug take-back program whenever possible. If a take-back site is unavailable, the medicine should be mixed with an undesirable substance, sealed in a bag, and then discarded in the household trash. The medication must not be flushed down the toilet or poured down a drain.